Regenxbio Inc (RGNX) gains 1.21% for July 21

Equities Staff  |

Regenxbio Inc (NASDAQ: RGNX) shares gained 1.21%, or $0.45 per share, to close Wednesday at $37.69. After opening the day at $37.26, shares of Regenxbio fluctuated between $37.77 and $36.55. 206,770 shares traded hands a decrease from their 30 day average of 307,275. Wednesday's activity brought Regenxbio’s market cap to $1,602,178,005.

Regenxbio is headquartered in Rockville, Maryland..

About Regenxbio Inc

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Visit Regenxbio Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Regenxbio Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Regenxbio Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content